CAC
ESPR

Cowen and Company’s Esperion Therapeutics ESPR Stock Holding History

Cowen and Company’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-25,000
Closed -$152K – 456
2020
Q2 		$152K Buy
+25,000
New +$1.05M 0.03% 218

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Cowen and Company's ESPR Position: Q2 2021 in Review

Cowen and Company sold out of Esperion Therapeutics (ESPR) in Q2 2021, closing a stake of 7,139 shares — an estimated $200K sold.

Cowen and Company first reported a position in ESPR in Q1 2021 and held it in 1 quarter. The position peaked at $200K in Q1 2021. 142 funds tracked by Wall St. Rank hold ESPR as of Q2 2021.

  • Cowen and Company reported no remaining Esperion Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Cowen and Company sold 7,139 Esperion Therapeutics shares in Q2 2021, an estimated $200K.
  • Cowen and Company first reported a position in Esperion Therapeutics in Q1 2021 and held it in 1 quarter.
  • Cowen and Company's Esperion Therapeutics position peaked at $200K in Q1 2021.
  • 142 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2021.

Based on Cowen and Company's 13F filing for Q2 2021, filed 13 Aug 2021.